Replimune’s advanced melanoma drug was declined approval by the Food and Drug Administration for a second time, the company announced on April 17. Sushil Patel, Replimune’s chief executive officer, said in a statement that the agency “has not exercised regulatory flexibility to meet patients’ needs.”
The debate highlights ongoing tensions between patient advocates seeking faster access to new therapies and regulators focused on maintaining rigorous standards. While some groups push for more flexible pathways, recent polling shows many Americans support slowing drug approvals to ensure proper testing.
FDA Commissioner Marty Makary’s administration has clarified that while regulatory flexibility is sometimes appropriate, it should not come at the expense of scientific rigor. Rahul Gupta, president of GATC Health and former director of the White House Office of National Drug Control Policy, said during a BioSpace webinar last month that this balance is key: “regulatory flexibility is appropriate, but not a waiver of rigor.”
Public opinion appears divided. A Politico poll found most Americans prefer stricter oversight even if it delays treatments. Meanwhile, a BioSpace LinkedIn poll revealed mixed views about whether the FDA strikes an appropriate balance: 34% felt it was too inflexible; 23% thought it too flexible; 19% believed the balance was right; and 24% were unsure.
The controversy over Replimune’s RP1 therapy reflects these complexities. The FDA cited heterogeneity in trial populations as grounds for both its first rejection last July and its latest decision this April—a stance at odds with scientists involved in designing the study who argued such diversity mirrors real-world conditions.
Peter Pitts, former FDA associate commissioner for external relations and current president of the Center for Medicine in the Public Interest, questioned whether agency standards are applied consistently or transparently enough to give sponsors confidence in planning development programs. He wrote that shifting expectations late in review processes undermines predictability rather than enhancing scientific rigor.
Efforts to clarify guidance continue within the agency. This week saw new draft safety guidelines published by the FDA aimed at standardizing gene editing therapy assessments—part of broader attempts to speed rare disease treatment development while maintaining safety benchmarks.
Industry observers say consistent application of guidance remains essential as clinical trial designs become more complex. Harpreet Singh from Precision for Medicine noted challenges around determining when innovative designs like externally-controlled trials are acceptable—an issue compounded by evolving agency positions during reviews.
Looking ahead, experts urge further clarity from regulators so companies can better align with expectations and avoid surprises late in approval processes.
